Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Twist Bioscience Corp (NASDAQ: TWST) closed at $32.12 down -2.01% from its previous closing price of $32.78. In other words, the price has decreased by -$2.01 from its previous closing price. On the day, 0.93 million shares were traded. TWST stock price reached its highest trading level at $33.31 during the session, while it also had its lowest trading level at $31.73.
Ratios:
For a deeper understanding of Twist Bioscience Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on November 04, 2025, initiated with a Overweight rating and assigned the stock a target price of $41. On December 13, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $60. On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.Guggenheim initiated its Buy rating on June 04, 2024, with a $53 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 08 ’25 when Cho Dennis sold 398 shares for $32.88 per share. The transaction valued at 13,085 led to the insider holds 145,004 shares of the business.
Leproust Emily M. sold 2,255 shares of TWST for $74,140 on Dec 08 ’25. The Chief Executive Officer now owns 875,918 shares after completing the transaction at $32.88 per share. On Dec 08 ’25, another insider, Green Paula, who serves as the SVP of Human Resources of the company, sold 877 shares for $32.88 each. As a result, the insider received 28,834 and left with 166,912 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 1964074496 and an Enterprise Value of 1822212608. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.22 while its Price-to-Book (P/B) ratio in mrq is 4.12. Its current Enterprise Value per Revenue stands at 4.839 whereas that against EBITDA is -15.942.
Stock Price History:
The Beta on a monthly basis for TWST is 2.19, which has changed by -0.32378948 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $23.30. The 50-Day Moving Average of the stock is 3.91%, while the 200-Day Moving Average is calculated to be -2.46%.
Shares Statistics:
For the past three months, TWST has traded an average of 1.75M shares per day and 1181320 over the past ten days. A total of 60.63M shares are outstanding, with a floating share count of 58.28M. Insiders hold about 4.69% of the company’s shares, while institutions hold 116.84% stake in the company. Shares short for TWST as of 1764288000 were 12752433 with a Short Ratio of 7.30, compared to 1761868800 on 10548267. Therefore, it implies a Short% of Shares Outstanding of 12752433 and a Short% of Float of 23.49.
Earnings Estimates
. The current market rating for Twist Bioscience Corp (TWST) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.47 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.76 and -$1.76 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.08, with 8.0 analysts recommending between -$0.64 and -$1.54.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $100.33M this quarter.It ranges from a high estimate of $101M to a low estimate of $100M. As of. The current estimate, Twist Bioscience Corp’s year-ago sales were $88.71MFor the next quarter, 6 analysts are estimating revenue of $105.08M. There is a high estimate of $109.1M for the next quarter, whereas the lowest estimate is $103.85M.
A total of 7 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $432.9M, while the lowest revenue estimate was $429.4M, resulting in an average revenue estimate of $430.84M. In the same quarter a year ago, actual revenue was $376.57MBased on 6 analysts’ estimates, the company’s revenue will be $497.01M in the next fiscal year. The high estimate is $503.8M and the low estimate is $485.63M.
